SNY logo

Sanofi Stock Price

Symbol: NasdaqGS:SNYMarket Cap: US$98.6bCategory: Pharmaceuticals & Biotech

SNY Share Price Performance

US$47.43
-4.68 (-8.98%)
US$47.43
-4.68 (-8.98%)
Price US$47.43

SNY Community Narratives

There are no narratives available yet.

Recent SNY News & Updates

No updates

Sanofi Key Details

€45.7b

Revenue

€13.1b

Cost of Revenue

€32.6b

Gross Profit

€26.2b

Other Expenses

€6.4b

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Oct 24, 2025
Earnings per share (EPS)
5.23
Gross Margin
71.32%
Net Profit Margin
13.96%
Debt/Equity Ratio
29.2%

Sanofi Competitors

 
 
 
 
 
 
 
 
 
 
 
 

About SNY

Founded
1994
Employees
82878
CEO
Paul Hudson
WebsiteView website
www.sanofi.com

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, yellow fever, and rabies vaccines. In addition, the company has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Innate Pharma SA for a natural killer cell engager program targeting B7-H3; and Blackstone Life Sciences to develop pivotal studies and clinical development program. Further, it has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop novel targeted protein degradation therapies; Denali Therapeutics Inc. to treat a range of systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for the discovery and development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab, as well as an strategic alliance with the Department of Health – Abu Dhabi for the development of global vaccines. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

French Market Performance

  • 7 Days: -2.8%
  • 3 Months: -1.5%
  • 1 Year: 3.5%
  • Year to Date: 1.6%
Over the last 7 days, the market has dropped 2.8%, driven by a decline of 5.3% in the Consumer Discretionary sector. In the last year, the market is actually up 3.5%. As for the next few years, earnings are expected to grow by 12% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading